SION
Sionna Therapeutics, Inc.
- Latest sale
- $21.8M
- Sep 17 · Unusual
- Form 4 sales
- 42
- On record
- Form 144 notices
- 0
- Proposed sales
- Next unlock
- None
- No lockup ahead
Lockups
No lockup on record.
Sales by reason
Timeline
- 1 Form 4 saleRoutineMay 27 2026
Sold 101 shares at $44.49 ($4k)
Orbimed Advisors LLC, Director
10b5-1 planSold 0% of holdings ($119M position)2.7M shares left0x usual sizeFiling
- 2 Form 4 saleRoutineMay 27 same day
Sold 101 shares at $44.49 ($4k)
Thompson Peter A., Director
10b5-1 planSold 0% of holdings ($119M position)2.7M shares left0x usual sizeFiling
- 3 Form 4 saleRoutineJun 30 +34 days
Sold 115,844 shares at $45.50 ($5.3M)
Orbimed Advisors LLC, Director
10b5-1 planSold 4.3% of holdings ($122M position)2.6M shares left1.1x usual sizeFiling
- 4 Form 4 saleRoutineJun 30 same day
Sold 115,844 shares at $45.50 ($5.3M)
Thompson Peter A., Director
10b5-1 planSold 4.3% of holdings ($122M position)2.6M shares left2.6x usual sizeFiling
- 5 Form 4 saleRoutineJul 6 +6 days
Sold 10,250 shares at $43.60 ($447k)
Fitzpatrick Jennifer, Chief Legal Officer
10b5-1 planSold 100% of holdings ($447k position)0 shares left1x usual sizeFiling
- 6 Form 4 saleRoutineJul 7 +1 day
Sold 85,918 shares at $44.86 ($3.9M)
OrbiMed Capital GP VIII LLC, Director
10b5-1 planSold 3.4% of holdings ($115M position)2.5M shares left2.8x usual sizeFiling
- 7 Form 4 saleRoutineJul 7 same day
Sold 85,918 shares at $44.86 ($3.9M)
Thompson Peter A., Director
10b5-1 planSold 3.4% of holdings ($115M position)2.5M shares left1.6x usual sizeFiling
- 8 Form 4 saleUnusualSep 17 +72 days
Sold 3.4M shares at $6.33 ($21.8M)
Ra Capital Management, L.P., Director, 10% owner
No 10b5-1 planSold 50% of holdings ($43.7M position)3.4M shares leftFiling
Every transaction
Loading transactions…
Sales, notices and lockups (42)
Export watchlist as CSV| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sep 17, 2026 | Ra Capital Management, L.P. | Director, 10% owner | Form 4 sale | 3.4M | $21.8M | 50.0% | Unusual | SEC |
| Jul 7, 2026 | Thompson Peter A. | Director | Form 4 sale | 85,918 | $3.9M | 3.4% | Routine | SEC |
| Jul 7, 2026 | OrbiMed Capital GP VIII LLC | Director | Form 4 sale | 85,918 | $3.9M | 3.4% | Routine | SEC |
| Jul 6, 2026 | Fitzpatrick Jennifer | Chief Legal Officer | Form 4 sale | 10,250 | $447k | 100.0% | Routine | SEC |
| Jun 30, 2026 | Thompson Peter A. | Director | Form 4 sale | 115,844 | $5.3M | 4.3% | Routine | SEC |
| Jun 30, 2026 | Orbimed Advisors LLC | Director | Form 4 sale | 115,844 | $5.3M | 4.3% | Routine | SEC |
| May 27, 2026 | Thompson Peter A. | Director | Form 4 sale | 101 | $4k | 0.0% | Routine | SEC |
| May 27, 2026 | Orbimed Advisors LLC | Director | Form 4 sale | 101 | $4k | 0.0% | Routine | SEC |
| May 11, 2026 | Thompson Peter A. | Director | Form 4 sale | 292,952 | $13.4M | 9.9% | Unusual | SEC |
| May 11, 2026 | Orbimed Advisors LLC | Director | Form 4 sale | 292,952 | $13.4M | 9.9% | Routine | SEC |
| Apr 18, 2026 | Thompson Peter A. | Director | Form 4 sale | 55,345 | $2.5M | 1.8% | Routine | SEC |
| Apr 18, 2026 | Orbimed Advisors LLC | Director | Form 4 sale | 55,345 | $2.5M | 1.8% | Routine | SEC |
| Apr 16, 2026 | Thompson Peter A. | Director | Form 4 sale | 510,583 | $22.9M | 14.5% | Unusual | SEC |
| Apr 16, 2026 | Orbimed Advisors LLC | Director | Form 4 sale | 510,583 | $22.9M | 14.5% | Routine | SEC |
| Mar 5, 2026 | Fitzpatrick Jennifer | Chief Legal Officer | Form 4 sale | 10,250 | $347k | 100.0% | Routine | SEC |
| Feb 3, 2026 | Thompson Peter A. | Director | Form 4 sale | 30,953 | $1.4M | 0.9% | Routine | SEC |
| Feb 3, 2026 | OrbiMed Capital GP VIII LLC | Director | Form 4 sale | 30,953 | $1.4M | 0.9% | Routine | SEC |
| Jan 22, 2026 | Winkelried Jon | 10% owner | Form 4 sale | 250,000 | $10M | 3.7% | No plan | SEC |
| Dec 24, 2025 | OrbiMed Capital GP VIII LLC | Director | Form 4 sale | 33,356 | $1.5M | 0.9% | Routine | SEC |
| Dec 24, 2025 | Thompson Peter A. | Director | Form 4 sale | 33,356 | $1.5M | 0.9% | Routine | SEC |
| Dec 19, 2025 | OrbiMed Capital GP VIII LLC | Director | Form 4 sale | 1,875 | $83k | 0.1% | Routine | SEC |
| Dec 19, 2025 | Thompson Peter A. | Director | Form 4 sale | 1,875 | $83k | 0.1% | Routine | SEC |
| Dec 5, 2025 | Fitzpatrick Jennifer | Chief Legal Officer | Form 4 sale | 10,250 | $415k | 100.0% | Routine | SEC |
| Nov 26, 2025 | Orbimed Advisors LLC | Director | Form 4 sale | 108,073 | $4.8M | 2.9% | Routine | SEC |
| Nov 26, 2025 | Thompson Peter A. | Director | Form 4 sale | 108,073 | $4.8M | 2.9% | Routine | SEC |
| Nov 21, 2025 | Kolchinsky Peter | Director, 10% owner | Form 4 sale | 30,316 | $1.2M | 16.0% | No plan | SEC |
| Nov 19, 2025 | Ra Capital Management, L.P. | Director, 10% owner | Form 4 sale | 136,351 | $5.5M | 44.8% | Unusual | SEC |
| Oct 28, 2025 | RA Capital Nexus Fund III, L.P. | Director | Form 4 sale | 373,610 | $14.8M | 64.1% | Unusual | SEC |
| Oct 21, 2025 | Cloonan Michael | President & CEO | Form 4 sale | 99,800 | $3.6M | 15.4% | Unusual | SEC |
| Oct 21, 2025 | Booth Bruce | Director | Form 4 sale | 88,878 | $3M | 11.5% | Routine | SEC |
| Oct 20, 2025 | Booth Bruce | Director | Form 4 sale | 286,369 | $9.3M | 29.0% | Unusual | SEC |
| Oct 16, 2025 | Cloonan Michael | President & CEO | Form 4 sale | 25,200 | $788k | 4.4% | Routine | SEC |
| Oct 15, 2025 | Booth Bruce | Director | Form 4 sale | 194,932 | $5.9M | 20.6% | Routine | SEC |
| Oct 6, 2025 | Booth Bruce | Director | Form 4 sale | 49,546 | $1.5M | 5.9% | Routine | SEC |
| Oct 1, 2025 | Booth Bruce | Director | Form 4 sale | 78,693 | $2.4M | 9.0% | Routine | SEC |
| Sep 29, 2025 | Cloonan Michael | President & CEO | Form 4 sale | 25,000 | $728k | 4.4% | Routine | SEC |
| Sep 4, 2025 | Fitzpatrick Jennifer | Chief Legal Officer | Form 4 sale | 10,250 | $237k | 100.0% | Routine | SEC |
| Sep 2, 2025 | Ridloff Elena | CFO & Head of Corp. Dev. | Form 4 sale | 9,584 | $240k | 19.9% | Routine | SEC |
| Aug 28, 2025 | Ridloff Elena | CFO & Head of Corp. Dev. | Form 4 sale | 23,416 | $602k | 32.7% | Routine | SEC |
| Aug 27, 2025 | Cloonan Michael | President & CEO | Form 4 sale | 25,000 | $624k | 4.4% | Routine | SEC |
| Aug 20, 2025 | Cloonan Michael | President & CEO | Form 4 sale | 25,000 | $569k | 4.4% | Routine | SEC |
| Aug 20, 2025 | Ridloff Elena | CFO & Head of Corp. Dev. | Form 4 sale | 52,000 | $1.1M | 42.1% | Routine | SEC |